Telescope Innovations Corp · CSE:TELI

Telescope Innovations — Investor Presentation (February 2024)

15 slides from Telescope Innovations's investor presentation, February 2024

  1. Slide 1: Fewer Experiments. More Insight.

    FEWER EXPERIMENTS. MORE INSIGHT.

  2. Slide 2: Disclaimer and forward-looking statements

    TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc

  3. Slide 3: Our Company

    TELI (CSE) OUR COMPANY TELIF (OTCQB) We build intelligent automation platforms that accelerate chemical process development, increase data quality, and reduce development costs. AUTOMATION & ADVANCED ARTIFICIAL PROCESS ROBOTICS ANALYTICAL TECHNOLOGY INTELLIGENCE DEVELOPMENT TELI (CSE) TELIF (OTCQB)

  4. Slide 4: Who We Are

    TELI (CSE) WHO WE ARE Our award-winning scientific leadership includes a 2-time Nobel Prize Winner in Chemistry. TELIF (OTCQB) We have collectively authored over 450 academic publications and 34 patents. PROF. JASON HEIN DR. BARRY SHARPLESS HENRY DUBINA DR. JEFF SHERMAN JOHN KIRINCIC CTO AND DIRECTOR

  5. Slide 5: Our Board of Directors

    TELI (CSE) OUR BOARD OF DIRECTORS Our directors bring over 80 years combined experience in building technology companies and TELIF (OTCQB) successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a

  6. Slide 6: Our Vision

    OUR VISION 1 2 3 International leadership in online Provider-of-choice for Global deployment in chemical and chemistry sampling and analysis products Self-Driving Laboratories pharmaceutical process development telescopeinnovations.com 6

  7. Slide 7: Flagship Product: DirectInject-LC

    TELI (CSE) FLAGSHIP PRODUCT A process analytical technology for automated TELIF (OTCQB) analysis of chemical reactions DIRECTINJECT - LCTM In first year of launch, units are deployed at 13 of the top 20 pharma companies in the “...automation, lab digitization, world and data-rich experimentation aren

  8. Slide 8: Global Process Analytical Technology (PAT) Market

    TELI (CSE) GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET* KEY TELIF (OTCQB) ● Massive, increasing R&D spending in pharma and biotech DRIVERS ● Need for automation and quality control in pharmaceutical manufacturing GLOBAL MARKET SIZE 2021 BREAKDOWN BY TECHNIQUE $4.3 B DirectInject-LC 4 addresses

  9. Slide 9: Strong Investments in Self-Driving Laboratories (SDLs)

    STRONG INVESTMENTS IN SELF-DRIVING LABORATORIES (SDLs) $CAD$CAD 500 M500 | 2023 M £ 81 M | 2018 Acceleration Consortium $200 M from government (CFREF) $200 M: Largest Canadian federal research grant (CFREF) Materials Innovation Factory + $300 M: Matching by industry & academic partners $300 M in mat

  10. Slide 10: Strategic Partners and Clients

    TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) SCIENTIFIC PHARMACEUTICAL ENGINEERING & MINING GOVERNMENT INSTRUMENTATION COMPANIES COMPANIES AND ACADEMIA COMPANIES telescopeinnovations.com 10 CONFIDENTIAL DRAFT

  11. Slide 11: Building a Successful Track Record

    TELI (CSE) BUILDING A SUCCESSFUL TRACK RECORD Repeat clients for TELIF (OTCQB) Self-Driving Labs in chemical and Second profitable DIRECTINJECT - LCTM pharmaceutical quarter closed deployed by 13 of top 20 pharma manufacturing (Q3, FY2023) companies in the world Telescope Advisor Telescope closes its

  12. Slide 12: Key Business Plan Elements for 2024 and 2025

    TELI (CSE) KEY BUSINESS PLAN ELEMENTS FOR 2024 AND 2025 SAMPLING / ANALYSIS SELF-DRIVING CHEMICAL / PHARMA TELIF (OTCQB) PRODUCTS LABORATORIES PROCESS DEVELOPMENT Global distribution of Formalize consortium of key Maintain and expand Process DIRECTINJECT - LC via market- pharma companies to fund Res

  13. Slide 13: Strong Growth in First Years

    TELI (CSE) TELIF (OTCQB) STRONG GROWTH IN FIRST 2 YEARS ● Revenue-positive in first full fiscal year (FY 2022) ● 375% increase in revenue from FY 2022 to FY 2023 ● Major development in FY 2024: Global Distribution Agreement signed with Market-leading vendor (Mettler Toledo AutoChem) for DirectInject-L

  14. Slide 14: Capitalization

    TELI (CSE) CAPITALIZATION STOCK TICKER SYMBOLS TELIF (OTCQB) TELI (CSE), TELIF(OTCQB) CAPITAL STRUCTURE PRICE NUMBER December 2023 Average Shares issued 53,665,569 Stock options $ 0.54 4,283,050 Warrants $ 0.75 2,439, 749 Fully Diluted Share Position 60,388,749 Shares held by Directors / Officers - 1

  15. Slide 15: Thank You

    THANK YOU Contact: [email protected]

Telescope Innovations — Investor Presentation (February 2024) on 6ix